FLT3 and acute myeloid leukemia: In a phase II study, midostaurin at a dose of 75 mg three times daily did not have sufficient clinical activity in 20 patients with relapsed or refractory FLT3-mutated AML; in addition, two patients died for treatment-related pulmonary events [49].